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As microbes become increasingly resistant to antibiotics,
and in many cases to several drugs simultaneously, the
search is on to find new therapies. One method to
combat resistance is to use inhibitors of resistance
mechanisms to potentiate existing antibiotics. Recent
efforts are encouraging and highlight the importance of
research at the chemistry–microbiology interface in
developing new approaches to tackle resistance. 
Address: Antimicrobial Research Centre, Department of Biochemistry,
McMaster University, 1200 Main St. W. Hamilton, ON, Canada,
L8N 3Z5.
E-mail: wrightge@fhs.csu.mcmaster.ca
Chemistry & Biology 2000, 7:R127–R132
1074-5521/00/$ – see front matter 
© 2000 Elsevier Science Ltd. All rights reserved.
Antibiotic resistance is a growing problem in the treatment
of infectious diseases caused by bacteria, fungi, parasites
and viruses. In particular, bacterial resistance to antibiotics
has emerged over the past decades as a major health
problem [1,2]. This is especially true in hospitals and
chronic care facilities, which provide strong selective pres-
sure for the emergence of resistance because of the large
quantities and the variety of antibiotics used in these envi-
ronments. All widely used antibiotics are now subject to
bacterial resistance and even some of the newer agents
such as the streptogramins and the new generation fluoro-
quinolones are finding a significant established resistance
levels as a result of similar compounds being used in medi-
cine and agriculture during the past several years. 
The challenge of antibiotic resistance has generally been
met in two ways: through the discovery of completely
novel antibiotics and by the use of derivatives of known
antibiotics — frequently prepared by semisynthetic
methods — that are not affected by existing resistance
mechanisms. Although completely novel classes of anti-
biotics were discovered and frequently implemented
rapidly into clinical practice throughout the 1940s and
1950s, a truly new antibiotic class has not emerged for
many years, perhaps since the discovery of the fluro-
quinolones in the early 1970s, which themselves were
derived from nalidixic acid discovered in the early 1960s.
This trend may now be changing with the advent of
several new antibacterial compounds, including the
oxazolidinones such as linezolid [3] and the lipopeptide
daptomycin [4]. In contrast, the variation or modification
of known antibiotics has been the major source of new
medicinal agents for decades. New β-lactams (e.g. methi-
cillin and oxacillin), aminoglycosides (e.g. tobramycin
and amikacin) and other antibiotics, very often prepared
by semisynthetic methods, have been the mainstay of
antibiotic drug discovery. 
An alternative to these two pathways towards new thera-
pies as a response to antimicrobial resistance is the devel-
opment of inhibitors of resistance mechanisms [5]. In this
approach, the antibiotic is co-administered with an
inhibitor that neutralizes the resistance mechanism and
consequently the antibiotic is still useful, even in resistant
organisms. This approach has the advantage of extending
the utility of antibiotics of known pharmacology, toxicol-
ogy, treatments schedules and so on, long after resistance
emerges. Given that there have been only a few new
antibiotics brought to clinical trials over the past decade,
despite the general agreement that such compounds are
greatly needed, this approach should find increasing favor. 
β-Lactams
The primary route of resistance to the β-lactam antibiotics
is through the production of hydrolytic enzymes termed
β-lactamases [6]. There is well-established clinical prece-
dent for the use of resistance inhibitors as potentiators of
antibiotic action in the β-lactam field [7,8]. Clavulanic acid
(1), sulbactam (2) and tazobactam (3) are β-lactam com-
pounds with only weak antimicrobial activity (Figure 1).
They are, however, inhibitors of nonmetallo β-lactamases
(principally of class A, Bush group 2) and are clinically
administered in conjunction with a β-lactam antibiotic
such as amoxicillin, ampicillin or piperacillin. These
inhibitory compounds act as covalent slow-dissociating
inhibitors of many serine β-lactamases through acylation
of the active-site serine (Figure 1). The β-lactam/inhibitor
combinations have been in clinical use for more than 15
years and find use in the treatment of infections caused by
a variety of both gram-negative (e.g. Escherichia coli and
Haemophilus influenzae) and gram-positive (e.g. Staphylococ-
cus aureus and Bacteroides sp.) bacteria. Not surprisingly,
the β-lactam/inhibitor combinations also are susceptible to
resistance and β-lactamases that can readily hydrolyze the
inhibitors have emerged [9]. Consequently, efforts to cir-
cumvent this emerging resistance through the chemical
modification of the inhibitors (e.g. [10]) or the develop-
ment of novel inhibitors (e.g. [11]) are under way.
Aminoglycosides
Resistance to the aminoglycoside antibiotics occurs pri-
marily through regiospecific chemical modification cata-
lyzed by O-phosphoryltransferases, N-acetyltransferases
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and O-adenyltransferases [12]. The broad dissemination
of these resistance mechanisms in pathogenic bacteria
has limited the use of aminoglycoside antibiotics such as
kanamycin, which is sensitive to all three mechanisms.
Traditionally, new compounds such as tobramycin, a
kanamycin analogue that lacks a key site of chemical
modification (3′-hydroxyl) yet retains antimicrobial
activity, have been introduced in response to the
growing resistance problem. 
The alternative approach of combining aminoglycosides
with inhibitors of specific aminoglycoside resistance
enzymes has been demonstrated to be effective in exper-
iments reported almost 20 years ago. The natural product 
7-hydroxytropolone (4; Figure 2) and derivatives were
shown to be micromolar inhibitors of ANT(2′′), an
aminoglycoside adenyltransferase widely found in gram-
negative pathogens [13]. Furthermore, compound 
4 reversed tobramycin and dibekacin resistance in E. coli
harboring the ant(2′′) gene, establishing the usefulness of
this strategy. 
Mobashery and colleagues at Wayne State University [14]
have prepared several novel aminoglycosides with the
potential to either inhibit or evade the action of resistance
enzymes. The synthesis of 2′-nitro derivatives of amino-
glycosides was the first example of mechanism-based inac-
tivation of an aminoglycoside-resistance enzyme. These
compounds are substrates for the widespread APH(3′)
enzymes that phosphorylate a hydroxyl group at position
3′, which is vicinal to the 2′NO2. Phosphorylation of 3′OH
generates compounds that can readily undergo nonenzy-
matic elimination to generate the nitroalkene, which pre-
sumably can undergo Michael addition by active-site
nucleophiles (Figure 3). Although these compounds were
not effective in reversing aminoglycoside resistance in
bacteria, the technology could be developed for use in
other contexts, as it should be applicable to a variety of
group transferases.
Very recently, the same group has reported the synthesis
of a 3′-oxo-aminoglycoside as a means of evading the
action of APH(3′) kinases [15]. In solution, the 3′-keto
derivative is expected to be hydrated and therefore is a
potential substrate for APH(3′). The resulting
3′-phospho-derivative is, however, unstable as a result of
the ketone-diol equilibrium and the leaving group nature
of the phosphate. The antibiotic is therefore readily
regenerated nonenzymatically (Figure 4). The compound
does not seek to inhibit resistance enzymes as a means to
potentiate antibiotics; instead, this aminoglycoside is
simply not affected by the presence of resistance
enzymes through a bit of clever chemistry. The 3-keto
derivative of kanamycin was not as effective an antibiotic
as the parent compound, as assessed by its MIC (the con-
centration of antibiotic required to achieve complete inhi-
bition of growth), which was 250 µg/ml versus 
8 µg/ml for kanamycin. The ketone did, however, lower
the MIC 4–8-fold in the presence of the resistance
enzyme APH(3′)-Ia. Unlike the next-generation antibi-
otics that seek to evade resistance by being poor sub-
strates for existing resistance enzymes, the use of
self-regenerating antibiotics such as 3′-keto-aminoglyco-
sides could reduce the selective pressure that fuels the
evolution of resistance mechanisms. 
Finally, as representative three-dimensional structures
emerge for aminoglycoside-resistance enzymes, new
opportunities are arising to exploit these in inhibitor
design. For example, the structural and functional homol-
ogy between APH(3′)-IIIa and Ser/Thr/Tyr kinases
[16,17] is paralleled by sensitivity to several inhibitors of
protein kinases [18]. Ongoing synthetic efforts to develop
libraries of protein kinase inhibitors in the pharmaceutical
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Figure 1
Structure and general mechanism of action of
medically important β-lactamase inhibitors.
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and biotechnology industries could therefore simultane-
ously generate compounds with the capacity to reverse
antibiotic resistance, if screened appropriately.
Macrolides 
Resistance to the macrolide antibiotics such as erythro-
mycin and azithromycin occurs primarily as a result of
specific base methylation of the bacterial 23S ribosomal
RNA catalyzed by the Erm family of methyltransferases
[19]. Furthermore, this site-specific methylation at the
peptidyl transfer site on the ribosome also confers resis-
tance to the lincosamide antibiotics such as clindamycin
and the B class streptogramins antibiotics such as quin-
upristin, a component of the drug Synercid. Efforts to
Minireview  Chemical strategies for combating antibiotic resistance Wright    R129
Figure 2
Structures of compunds referred to in the text
that inhibit antibiotic resistance mechanisms
or have antimicrobial activity.
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Figure 3
Proposed inactivation of aminoglycoside
3′-kinases by 2′-nitro aminoglycoside
derivatives. O
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discover drug-like molecules capable of inhibiting the
Erm methytransferases have been reported recently. A
screen of 160,000 compounds yielded nine novel chemi-
cals that inhibited ErmC methyltransferase from 
S. aureus, five with IC50 values of < 5 µM [20]. Some of
these compounds in combination with the macrolide
antibiotic azithromycin demonstrated synergistic growth
inhibition against several bacteria, demonstrating that
the approach of inhibitor/antibiotic combinations is a
feasible route to combat Erm-based resistance. 
Recently, the group of Fesik at Abbott laboratories [21,22]
used their  SAR by NMR (structure-based activity relation-
ship by nuclear magnetic resonance) method, in which mix-
tures of small molecules are probed for interaction with a
target enzyme by monitoring changes in the 15N/1H chemi-
cal shifts to identify several leads for Erm inhibitors [23].
The study therefore yielded several classes of new com-
pounds that could be used to potentiate the antimicrobial
activities of the macrolide lincosamide and streptogramin B
classes of drugs in the presence of Erm methyltransferases.
Efflux mechanisms
Efflux plays an important role in resistance not only to
antibacterial agents such as the fluoroquinolones and
tetracyclines, but also to antifungal, antimalarial and anti-
cancer drugs as well [24]. Membrane-bound pumps of
both the multidrug resistance ABC transporter and proton-
dependent major facilitator families mediate resistance by
efflux. These pumps can have narrow or broad compound
specificities and are widespread in both gram-negative
and gram-positive bacteria. Inhibition of efflux pumps as a
mechanism of potentiating antibiotic activity has been an
area of vigorous research.
Tetracycline resistance occurs either through active
efflux or by protection of the ribosomal target [25]. Ana-
logues of tetracycline, including 13-cyclopentylthio-
5-hydroxy-6-dexoytetracycline (5), have been shown to
inhibit the efflux protein TetB in everted membrane
vesicles [26]. Recently, this compound has been demon-
strated to potentiate the antibiotic activity of doxycy-
cline against E. coli bearing either the closely related
TetA or TetB efflux systems, but not against the gram-
positive organisms S. aureus or Enterococcus hirae express-
ing the more distantly related TetK or TetL efflux
pumps [27]. These results are encouraging but also
reveal the challenges that multiple resistance determi-
nants present to efforts to provide broad-spectrum
strategies for reversal of resistance.
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Figure 4
Self regeneration of 3′-ketoaminoglycosides
following phosphorylation by aminoglycoside
3′-kinases.O
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Figure 5
Light inactivation of a β-lactam antibiotic.
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In addition to the problem of multiple resistance genes
found in different organisms, certain bacteria are known
to express several different efflux systems [28,29]. For
example, four such systems have been identified in the
opportunistic pathogen Pseudomonas aeruginosa: MexAB-
OprM [30], MexCD-OprJ [31], MexEF-OprN [32] and
MexXY [33]. Compounds that simultaneously inhibit all
three mechanisms have been recently identified using
compound library screening followed by lead optimization
by researchers at Microcide Pharmaceuticals and Daichi
Pharmaceutical Company [5]. The dipeptide 6 (Figure 2)
was shown to potentiate the antipseudomonal activity of
the fluoroquinonlone levofloxacin in vitro, and it was also
effective in a mouse model for P. aeruginosa infection.
The major multidrug-resistance pump in S. aureus responsi-
ble for fluoroquinolone resistance is NorA, a chromosomally
encoded multidrug-resistance pump that confers resistance
upon overexpression [34,35]. The natural product reserpine
(7; Figure 2) has been known for a number of years to
inhibit the action of the NorA [34] and to potentiate the
action of the fluoroquinolone antibiotic norfloxacin [36]. An
interesting and important finding in these studies is that not
only did resperpine reduce the MIC for norfloxaxin, but
addition of the NorA inhibitor to the growth medium also
decreased the rate of emergence of high-level resistance
[36]. If this observation is found to be generally applicable,
then this provides yet more impetus for the discovery and
implementation of inhibitors of resistance. 
The neurotoxic properties of reserpine prompted a search
for small-molecule inhibitors of NorA using a commercial
compound library [37]. A screen of 9600 compounds
resulted in five candidate inhibitors of NorA, all of which
could potentiate the activity of the fluoroquinolone antibi-
otic ciprofloxacin against S. aureus. Furthermore, these com-
pounds also retained the capacity to diminish the rate of
emergence of fluoroquinolone resistance, mirroring the
properties of reserpine. 
Although the mechanism-based and random screening
approaches to the discovery of antibiotic potentiating
molecules are proving very successful, a creative approach
to the problem was recently reported by the Lewis lab at
Tufts University [38]. These researchers previously
observed that the antistaphylococcal properties of the
plant alkaloid berberine (8; Figure 2) were significantly
increased in the absence of NorA [35]. They then rea-
soned that, as alkaloids such as berberine are substrates
for bacterial efflux pumps, perhaps plants may have co-
evolved efflux inhibitors that could preserve the antimi-
crobial activity of the compounds. A screen of leaf
extracts of the berberine producer Berberis fremontii
resulted in the isolation of 5′-methoxyhydnocarpin (9;
Figure 2), a potent NorA inhibitor that potentiated the
antimicrobial activity of berberine (16-fold decrease in
MIC) and norfloxacin (fourfold decrease in MIC) against
S. aureus [38]. These results reveal that plants have the
potential to use compound synergy to increase the
potency of secondary metabolites, and alert us to the
utility of natural product screens in the search for poten-
tiators of antimicrobial activity.
Antibiotic volatility 
One of the driving forces of the maintenance of resistance
is the veritable pollution of hospital and agricultural envi-
ronments with antimicrobial compounds, which are gener-
ally chemically stable, long-lasting molecules. This
provides constant selective pressure for the maintenance
of resistance genes by bacterial populations exposed to
these compounds. Recently, an innovative approach to
decreasing resistance has emerged from the lab of Shahriar
Mobashery. This group has synthesized and characterized
a photolabile β-lactam antibiotic (10; Figure 2). The 
synthesis of a cephalosporanic acid derivatized with a
hydrazine functionality at position C7b that is masked by
a light sensitive o-nitrobenzyloxycarbonyl group provides
a built-in light-activated ‘autodestruct timer’ for the inacti-
vation of the antibiotic. Loss of the o-nitrobenzyloxycar-
bonyl upon exposure to light reveals the hydrazine
moiety, which can now participate in an intermolecular
ring expansion with the β-lactam ring, precipitating degra-
dation of the antibiotic into non-antimicrobial byproducts
(Figure 5). This approach provides an excellent example
of the creative application of novel chemistry to reduce
the selective pressure generated by the tons of antimicro-
bials released into the environment every year. 
Future prospects
The examples cited in this minireview show that new
strategies to combat antibiotic resistance are emerging
through innovative approaches to develop new antibiotics
or to discover potentiators of antimicrobial action. 
There is no definitive cure for antibiotic resistance.
Faced with the relentless power of natural selection, only
a continuing strategy of vigilance, creativity and pre-
paredness will ensure that the antibiotic era continues
well into this century.
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